Inimmune to Present Trial-in-Progress Poster on First-in-Human Study of INI-4001, a Novel TLR7/8 Agonist, at ASCO 2025
Missoula, MT, May 29, 2025 – Inimmune Corporation, a clinical-stage biotechnology company focused on developing next-generation immunotherapies, today announced that it will present a Trial-in-Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30–June 3, 2025, in Chicago, IL. The poster, titled “A first-in-human phase 1 clinical trial […]
Inimmune to Present Key Updates at the 2025 World Vaccine Congress in Washington, DC April 21-24
Missoula, MT, April 15, 2025 – Inimmune, a clinical-stage biotechnology company specializing in next generation vaccine adjuvants, immunotherapies, and delivery systems, is excited to announce its participation in the 2025 World Vaccine Congress, taking place April 21–24 in Washington, DC. The company will share exciting progress from its clinical-stage immunotherapy and vaccine programs, and take […]
Inimmune Welcomes Dr. Heather Madsen of Hatteras Venture Partners to Board of Directors
Missoula, MT, February 28, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies, is pleased to announce the appointment of Dr. Heather Madsen to its Board of Directors. Dr. Madsen, a distinguished life sciences executive and Operating Partner at Hatteras Venture Partners, brings extensive expertise in the creation of high-performing life science […]
Inimmune to present successful Phase I allergy trial results at the American Academy of Allergy Asthma & Immunology meeting in San Diego, February 28-March 3, 2025
Missoula, MT, February 26, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies for cancer, allergy, autoimmunity, and vaccines will attend the AAAAI meeting in San Diego from February 28-March 3 where Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on Inimmune’s clinical stage treatment for seasonal […]
SPI Pharma, Inc. and Inimmune, Corp. Launch Partnership to Commercialize Advanced Adjuvant Systems
Wilmington, Delaware, October 22, 2024 – SPI Pharma, Inc., a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, finalized their partnership to bring two adjuvant systems to market. The partners will launch these novel adjuvant systems at the […]
Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery
Cambridge, Mass, September 13, 2024 – Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics. Chemistry42, a multi-agent reinforcement learning system designed […]
Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist
MISSOULA, Montana, July 24, 2024 – Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with advanced solid tumors. This is an open-label, multiple-ascending dose, two-part dose […]
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
MISSOULA, Montana, July 16, 2024 – SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. […]
Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004
MISSOULA, Montana, May 15, 2024 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis (NCT06038279). In response to ragweed challenge, participants […]
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
MISSOULA, Montana, January 8, 2024 – Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its […]
